Latest Octagon Capital Advisors LP Stock Portfolio
Octagon Capital Advisors LP Performance:
2025 Q4: 27.36%YTD: 104.18%2024: -10.25%
Performance for 2025 Q4 is 27.36%, and YTD is 104.18%, and 2024 is -10.25%.
About Octagon Capital Advisors LP and 13F Hedge Fund Stock Holdings
On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, Octagon Capital Advisors LP reported an equity portfolio of $823.7 Millions as of 31 Dec, 2025.
The top stock holdings of Octagon Capital Advisors LP are , , COGT. The fund has invested 12.4% of it's portfolio in ABIVAX SA and 12.1% of portfolio in DIANTHUS THERAPEUTICS INC.
The fund managers got completely rid off MERUS N V (MRUS), APELLIS PHARMACEUTICALS INC (APLS) and NUVATION BIO INC (NUVB) stocks. They significantly reduced their stock positions in DBV TECHNOLOGIES S A (DBVT), ABIVAX SA and GOSSAMER BIO INC (GOSS). Octagon Capital Advisors LP opened new stock positions in ALUMIS INC, PALISADE BIO INC (PALI) and RAPT THERAPEUTICS INC (RAPT). The fund showed a lot of confidence in some stocks as they added substantially to KYMERA THERAPEUTICS INC (KYMR) and MIND MEDICINE MINDMED INC (MNMD).
The top stock holdings of Octagon Capital Advisors LP are , , COGT. The fund has invested 12.4% of it's portfolio in ABIVAX SA and 12.1% of portfolio in DIANTHUS THERAPEUTICS INC.
The fund managers got completely rid off MERUS N V (MRUS), APELLIS PHARMACEUTICALS INC (APLS) and NUVATION BIO INC (NUVB) stocks. They significantly reduced their stock positions in DBV TECHNOLOGIES S A (DBVT), ABIVAX SA and GOSSAMER BIO INC (GOSS). Octagon Capital Advisors LP opened new stock positions in ALUMIS INC, PALISADE BIO INC (PALI) and RAPT THERAPEUTICS INC (RAPT). The fund showed a lot of confidence in some stocks as they added substantially to KYMERA THERAPEUTICS INC (KYMR) and MIND MEDICINE MINDMED INC (MNMD).
Octagon Capital Advisors LP Annual Return Estimates Vs S&P 500
Our best estimate is that Octagon Capital Advisors LP made a return of 27.36% in the last quarter. In trailing 12 months, it's portfolio return was 104.18%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| alumis inc | 24,699,600 |
| palisade bio inc | 22,484,600 |
| bioage labs inc | 21,141,500 |
| rapt therapeutics inc | 19,441,400 |
| lexeo therapeutics inc | 17,129,200 |
| evommune inc | 8,560,000 |
| precision biosciences inc | 7,978,860 |
New stocks bought by Octagon Capital Advisors LP
Additions
| Ticker | % Inc. |
|---|---|
| kymera therapeutics inc | 48.61 |
| mind medicine mindmed inc | 4.69 |
Additions to existing portfolio by Octagon Capital Advisors LP
Reductions
| Ticker | % Reduced |
|---|---|
| dbv technologies s a | -43.6 |
| abivax sa | -42.94 |
| gossamer bio inc | -18.38 |
| cogent biosciences inc | -18.24 |
| corbus pharmaceuticals hldgs | -14.35 |
| centessa pharmaceuticals plc | -9.64 |
| pharvaris n v | -7.08 |
| taysha gene therapies inc | -2.29 |
Octagon Capital Advisors LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| nuvation bio inc | -9,743,340 |
| apellis pharmaceuticals inc | -20,446,200 |
| merus n v | -28,998,200 |
| neurogene inc | -4,367,160 |
| maze therapeutics inc | -4,606,900 |
| structure therapeutics inc | -3,220,000 |
| nuvation bio inc | -385,214 |
Octagon Capital Advisors LP got rid off the above stocks
Sector Distribution
Octagon Capital Advisors LP has about 56.9% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 56.9 |
| Others | 43.1 |
Market Cap. Distribution
Octagon Capital Advisors LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- SMALL-CAP
- MID-CAP
- MICRO-CAP
| Category | % |
|---|---|
| UNALLOCATED | 43.1 |
| SMALL-CAP | 29.2 |
| MID-CAP | 22.2 |
| MICRO-CAP | 5.5 |
Stocks belong to which Index?
About 29.6% of the stocks held by Octagon Capital Advisors LP either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 70.4 |
| RUSSELL 2000 | 29.6 |
Octagon Capital Advisors LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Octagon Capital Advisors LP
Octagon Capital Advisors LP has 26 stocks in it's portfolio. About 67.4% of the portfolio is in top 10 stocks. CRBP proved to be the most loss making stock for the portfolio. COGT was the most profitable stock for Octagon Capital Advisors LP last quarter.
Last Reported on: 17 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| APLS | apellis pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CDTX | cidara therapeutics inc | 2.68 | 100,000 | 22,089,000 | unchanged | 0.00 | ||
| CNTA | centessa pharmaceuticals plc | 2.28 | 750,000 | 18,757,500 | reduced | -9.64 | ||
| COGT | cogent biosciences inc | 10.13 | 2,350,000 | 83,472,000 | reduced | -18.24 | ||
| CRBP | corbus pharmaceuticals hldgs | 0.94 | 955,000 | 7,773,700 | reduced | -14.35 | ||
| DBVT | dbv technologies s a | 1.34 | 574,200 | 11,007,400 | reduced | -43.6 | ||
| DTIL | precision biosciences inc | 0.97 | 1,918,000 | 7,978,860 | new | |||
| GOSS | gossamer bio inc | 5.24 | 13,915,400 | 43,137,600 | reduced | -18.38 | ||
| KALV | kalvista pharmaceuticals inc | 2.50 | 1,273,330 | 20,564,300 | unchanged | 0.00 | ||
| KYMR | kymera therapeutics inc | 5.05 | 535,000 | 41,628,400 | added | 48.61 | ||
| MNMD | mind medicine mindmed inc | 3.62 | 2,230,000 | 29,859,700 | added | 4.69 | ||
| MRUS | merus n v | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| NUVB | nuvation bio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| NUVB | nuvation bio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| OCUL | ocular therapeutix inc | 3.87 | 2,623,600 | 31,850,500 | reduced | -0.02 | ||
| PALI | palisade bio inc | 2.73 | 9,567,900 | 22,484,600 | new | |||
| PEPG | pepgen inc | 0.55 | 700,000 | 4,557,000 | unchanged | 0.00 | ||
| PHVS | pharvaris n v | 2.26 | 671,465 | 18,633,200 | reduced | -7.08 | ||
| RAPT | rapt therapeutics inc | 2.36 | 574,000 | 19,441,400 | new | |||
| TRVI | trevi therapeutics inc | 4.28 | 2,815,000 | 35,243,800 | unchanged | 0.00 | ||